Cancer
Conditions
Interventions
Substudy 1:None
Intervention Group, Substudy 2:In the intervention group, the operating surgeon shall perform local infiltration anesthesia with liposomal bupivacaine (20 ml: 266 mg) at the surgical incision site
Control Group, Substudy 2:In the control group, the operating surgeon shall perform local infiltration anesthesia with 20 ml of 0.5% ropivacaine at the surgical incision site
Intervention Group, Substudy 3:In the intervention group, bilateral transversus abdominis plane block combined with bilateral posterior rectus sheath block shall be performed with liposomal bupivacain
the local anesthetic solution was injected into the bilateral transversus abdominis plane and posterior rectus sheath separately, with 20 ml administered at each site).
Control Group, Substudy 3:In the control group, bilateral transversus abdominis plane block combined with bilateral posterior rectus sheath block shall be performed with 0.25% ropivacaine (a total vol
Sponsors
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age: Patients aged >=18 years; 2.Language proficiency: Patients are able to fluently use the language of the questionnaires provided by the study; 3.Informed consent: Patients have provided written informed consent for study participation; 4.Patient type: Patients scheduled to undergo thoracoscopic radical resection for lung cancer (Substudy 1); 5.Patient type: Patients scheduled to undergo laparoscopic upper abdominal surgery (including hepatobiliary, pancreatic, gastric, duodenal and other related procedures) (Substudy 2); 6.Patient type: Patients scheduled to undergo laparoscopic lower abdominal surgery (including colorectal, gynecological, urological and other related procedures) (Substudy 3).
Exclusion criteria
Exclusion criteria: 1.Patients with a history of pre-existing chronic pain; 2.Cognitive impairment; 3.Inability to complete the Visual Analogue Scale (VAS); 4.A history of hypersensitivity to any study medications (Substudy 2, 3); 5.Severe central and peripheral nervous system diseases (Substudy 3); 6.Cardiac insufficiency, including Grade ?-? atrioventricular block or atrial fibrillation (Substudy 3); 7.Coagulation dysfunction, or the presence of infection, inflammation or injury at the puncture site (Substudy 3); 8.Severe hepatic and renal dysfunction (Substudy 3); 9.Severe cardiopulmonary dysfunction (Substudy 3); 10.Patients with other conditions deemed ineligible for trial participation by the investigator (Substudy 3).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BPI Score for Acute Pain at 24 Hours Postoperatively (Substudy 2, Substudy 3);Incidence of chronic postoperative pain at 3 months after surgery (Subestudy 1); | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain score at 3 months after surgery (Substudy 2, Substudy 3); | — |
Countries
China
Contacts
Public ContactHui Zheng
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed